11 completed, 1 unknown. 9 Phase 2, 2 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 9 | Completed 8, Unknown 1 |
| Phase 1 | 2 | Completed 1, Unknown 1 |
| Phase 3 | 2 | Completed 2 |
Follow etirinotecan pegol: new trials by email Literature Review of etirinotecan pegol trials Research Report on etirinotecan pegol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Preliminary Efficacy of JK1201I in Patients With SCLC JK-1201I - Small Cell Lung Cancer (SCLC) | Phase 1 / Phase 2 | Unknown | JenKem Technology Co., Ltd. | 63 | 2021-11-11 | 2022-01-05 |
| A Study of Etirinotecan Pegol (NKTR-102) Versus Treatment of Physician's Choice (TPC) in Patients With Metastatic Breast Cancer Who Have Stable Brain Metastases and Have Been Previously Treated With an Anthracycline, a Taxane, and Capecitabine NKTR-102, Eribulin, Ixabepilone - Metastasis, Breast Cancer | Phase 3 | Completed | Nektar Therapeutics | 178 | 2016-11-01 | 2023-04-14 |
| Phase 2 Etirinotecan Pegol in Refractory Brain Metastases & Advanced Lung Cancer / Metastatic Breast Cancer Pegylated Irinotecan - Stage IV Non-small Cell Lung Cancer (NSCLC), Recurrent Non-small Cell Lung Cancer (NSCLC) | Phase 2 | Completed | Joel Neal | 27 | 2015-08-01 | 2023-12-12 |
| A Study in Cancer Patients to Evaluate the Effect of a Single Dose of NKTR-102 (Etirinotecan Pegol) on the QTc Interval and to Assess Pharmacokinetics and Safety NKTR-102 - Advanced Cancer, Metastatic Solid Tumors | Phase 1 | Completed | Nektar Therapeutics | 33 | 2014-02-01 | 2016-12-22 |
| Pegylated Irinotecan NKTR 102 in Treating Patients With Relapsed Small Cell Lung Cancer Laboratory Biomarker Analysis, Pegylated Irinotecan, Pharmacological Study - Recurrent Small Cell Lung Carcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 38 | 2013-08-29 | 2020-03-17 |
| Etirinotecan Pegol (NKTR-102) in NSCLC Etirinotecan pegol (NKTR-102) - Metastatic Non Small Cell Lung Cancer, Recurrent Non Small Cell Lung Cancer | Phase 2 | Completed | Abramson Cancer Center at Penn Medicine | 40 | 2013-01-01 | 2020-04-03 |
| Phase II NKTR-102 In Bevacizumab-Resistant High Grade Glioma Etirinotecan pegol - Anaplastic Astrocytomas, Anaplastic Oligodendrogliomas | Phase 2 | Completed | Lawrence Recht | 20 | 2012-07-01 | 2016-02-24 |
| The BEACON Study (Breast Cancer Outcomes With NKTR-102) NKTR-102, Treatment of Physician's Choice (TPC) - Locally Recurrent Breast Cancer, Metastatic Breast Cancer | Phase 3 | Completed | Nektar Therapeutics | 852 | 2011-12-01 | 2021-06-01 |
| An Extension Study of NKTR-102 in Cancer Patients Previously Enrolled in NKTR-102 Studies NKTR-102 145 mg/m2, NKTR-102 120 mg/m2, NKTR-102 95 mg/m2 - Malignant Solid Tumor | Phase 2 | Completed | Nektar Therapeutics | 27 | 2011-10-01 | 2021-07-12 |
| NKTR-102 Versus Irinotecan in Patients With Second-Line, Irinotecan-Naïve, KRAS Mutant, Colorectal Cancer NKTR-102, irinotecan - Colorectal Cancer | Phase 2 | Completed | Nektar Therapeutics | 83 | 2008-12-01 | 2021-07-12 |
| Study to Evaluate the Safety and Efficacy of NKTR-102 in Patients With Metastatic or Locally Advanced Breast Cancer NKTR-102 - Tumor, Breast Cancer | Phase 2 | Completed | Nektar Therapeutics | 70 | 2008-10-01 | 2018-07-09 |
| NKTR-102 in Combination With Cetuximab in Patients With Refractory Solid Tumors (Phase 2a) and Metastatic or Locally Advanced Colorectal Cancer (Phase 2b) NKTR-102 100 mg/m2, NKTR-102 125 mg/m2, Cetuximab - Tumor, Colorectal Cancer | Phase 2 | Completed | Nektar Therapeutics | 18 | 2008-02-01 | 2021-07-12 |
Breast Neoplasms (4) · Small Cell Lung Carcinoma (3) · Carcinoma, Non-Small-Cell Lung (2) · Colorectal Neoplasms (2) · Neoplasm Metastasis (2) · Neoplasms (2) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma (1) · Glioblastoma (1) · Oligodendroglioma (1)
Nektar Therapeutics (7) · Abramson Cancer Center at Penn Medicine (1) · JenKem Technology Co., Ltd. (1) · Joel Neal (1) · Lawrence Recht (1) · Roswell Park Cancer Institute (1)
United States (11) · Belgium (5) · United Kingdom (4) · Spain (3) · Canada (2) · France (2) · Germany (2) · Italy (2) · Australia (1) · China (1) · India (1) · Israel (1) · Netherlands (1) · Portugal (1) · Russia (1)
Alison Hannah, MD (2) · Charu Aggarwal, MD (1) · Hongbin Chen, MD (1) · Ivan Gergel, MD (1) · Joel Neal (1) · Lawrence Recht, MD (1) · Xuan Zhao, Ph.D. (1)
PMID 24095299, PMID 26482278, PMID 28360015, PMID 28612225, PMID 30957581, PMID 31074641, PMID 35552364, PMID 40877204
P30CA016056 (1)